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Anthony Brusadin RN, BSN, CCRN 
Otterbein University, Westerville, Ohio 
What is the Topic 
• Parkinson’s Disease (PD) is a progressive neurodegenerative brain 
disorder (Lotankar et al, 2017) 
Why Parkinson’s 
• PD is the fast-growing neurological disorder, it is estimates that 
the number of PD case will double from about 7 million in 2015 to 
about 13 million in 2040 (Jankovic & Tan, 2020). 
• Neurological disorders Are the leading source of disability 
(Jankovic & Tan, 2020). 
• Growing elderly population (Simon et al, 2019). 
Signs and Symptoms 
• PD manifests as tremors, muscle rigidity, bradykinesia, impaired 
posture, impaired balance, speech changes, impaired fine motor 
skills and eventually loss of automatic movement (Radhakrishnan 
& Goyal, 2018). 
• Addition’s problems associated with PD are difficulties thinks, 
depression, issues swallowing, chewing, and eating, sleeping 
disorders, bladder issues, and constipation (Lotankar et al, 2017). 
• Patients can also have blood pressure changes, pain, fatigue, loss 
of smell and sexual dysfunction (Lotankar et al, 2017). 
Underlying pathophysiology 
• PD is a chronic progressive neurodegenerative disorder 
characterized by early prominent death of dopaminergic 
neurons in the substantia nigra pars compacta and 
widespread presence of alpha synuclein an intracellular 
protein (Radhakrishnan & Goyal, 2018). 
• PD is represented by the presence of neuronal inclusions, 
termed Lewis Bodies, mainly composed of aggregates of 
misfolded alpha synuclein which causes cytotoxicity through 
lipid membrane permeabilization, mitochondrial damage 
and oxidative stress (Vittorio et al, 2020). 
• Several risk factors have been implicated including pesticide 
and heavy metal exposure, rural living, agricultural 
occupation, traumatic head injury, history of melanoma, 
consumption of dairy products, type 2 diabetes mellitus 
(reduced using antidiabetic drugs), among many others 
(Jankovic & Tan, 2020). 
• Several life-style factors have been associated with reduced 
risk of developing PD. The most consistent association is a 
reduced risk of PD in cigarette smokers, caffeine, and 
exercise (Simon et al, 2019). 
• In recent years it has become evident that there is also a 
genetic contribution to PD and several mutations have been 
identified (SNCA, Parkin, PINK1, DJ1, LRRK2 and GBA) 
although in most world regions only a minority cases are 
explained by genetics (Lotankar et al, 2017). 
Figure 1. Parkinson’s patients have reduced dopamine levels in the synaptic cleft between neurons effecting the patient's movement 
(Radhakrishnan & Goyal, 2018). Image credit: Parkinson Association of the Carolinas 
Significance of Pathophysiology 
• Dopamine deficiency in the basal ganglia leads to classical 
Parkinsonian motor symptoms viz, bradykinesia, tremor, 
rigidity, and later postural instability (Radhakrishnan & 
Goyal, 2018). 
• While it is a rare condition, patients with Parkinson’s 
disease can suffer from vocal cord paralysis during 
intubation (Kim et al, 2020). 
• The pharmacological treatments for PD lose their efficacy as 
the disease progresses and are unable to block or reduce 
the neurodegenerative process (Vittorio et al, 2020). 
• The pathogenesis of PD involves neuroinflammation, which 
is affected by both innate and adaptive immunity. They have 
shown that the levels of proinflammatory cytokines are 
elevated in PD patients (Hwang et al, 2020). 
• Patients with PD also have higher rates of postoperative 
morbidity, which can be related to postural instability places 
these patients at greater risk of falling, whilst dysphagia 
increases susceptibility to aspiration pneumonia (Roberts & 
Lewis, 2018). 
Treatment 
• To date, the therapies available for the treatment of PD are 
addressed to reduce the motor symptoms and include the 
administration of drugs able to restore the level of dopamine 
(Vittorio et al, 2020). 
• Levodopa, the most effective drug in the treatment of PD, is 
almost always combined with carbidopa or benserazide, 
aromatic acid decarboxylase inhibitors that prevent its 
peripheral metabolism and markedly reduce the risk of nausea 
(Jankovic & Tan, 2020). 
• Dopamine receptor agonists stimulate dopamine receptors 
when introduced early during PD treatment, they delay 
levodopa related complications such as motor fluctuations and 
dyskinesias (Jankovic & Tan, 2020). 
• Subthalamic nucleus deep brain stimulation is an effective 
treatment for patients with Parkinson’s disease with motor 
fluctuations, but clinical outcomes are critically dependent on 
accurate placement of the stimulating electrode (Tsai et al, 
2020). 
• General anesthesia does not impair electrode placement 
accuracy or affect long-term clinical outcome (Tsai et al, 2020). 
• There is currently no cure for PD (Lotankar et al, 2017). 
• New research shows that inhibition of a-syn aggregation by 
small molecules proved to be a valid approach for the 
development of new therapeutics for the treatment of PD 
(Vittorio et al, 2020). 
Implications of Nursing Care 
• Recommend that evaluation of respiratory function should be 
performed carefully prior to surgery and antiparkinsonian drugs 
should be continued (Kim et al, 2020). 
• Recommend anesthetist to prepare for life-threatening upper 
airway obstruction during the perioperative period in patients 
with PD (Kim et al, 2020). 
• Several retrospective studies have found an association 
between anesthetic exposure during infancy and adverse 
neurodevelopmental outcomes (Roberts & Lewis, 2018). 
• Carefully reviewing a patient’s medication regimen so staff 
understand the importance of adhering to specific dosing 
intervals (Roberts & Lewis, 2018). 
Conclusion 
• PD is a complex disorder, with both environmental and genetic 
factors converging on a common set of pathways (Simon et al, 
2019). 
• While studies show a connection to anesthesia and adverse 
neurodevelopmental outcomes, there is not enough data to 
drawl a correlation between anesthesia and PD (Roberts & 
Lewis, 2018). 
• The inhibition of a-syn aggregation has emerged as promising 
new therapeutic strategy for the treatment of PD PD (Vittorio et 
al, 2020). 
• current PD research demands a search for unique biomarkers 
that can be useful to discriminate between PD and other 
diseases with higher sensitivity and specificity (Lotankar et al, 
2017). 
Figure 2.. Subthalamic nucleus deep brain stimulation are surgically 
implanted into the patient's brain to help stimulate the brain an reduce 
tremors (Tsai et al, 2020). Image credit: Smith 2021 
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